Procter & Gamble Ends Collaboration on ATI-7505 « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
July 2008

M T W T F S S

« Jun Aug »

1 2 3 4 5 6

7 8 9 10 11 12 13

14 15 16 17 18 19 20

21 22 23 24 25 26 27

28 29 30 31

Procter & Gamble Ends Collaboration on ATI-7505

Posted on July 2, 2008 by crimsoncanary

Procter & Gamble has ended its collaboration with ARYx Therapeutics for development and commercialization of 5-HT4 agonist ATI-7505 for chronic constipation and functional dyspepsia.

Filed under: Uncategorized | Tagged: 5-HT4, 5HT4, agonist, ARYx, ATI-7505, ATI7505, Licensing, Procter & Gamble

« ARYx 5HT4 agonist ATI-7505 shows favorable QT profile EU approves Relistor for Opioid-Induced Constipation In Advanced Illness Patients »

Leave a Reply